Acerta Pharma BV

Vincerx has seen its stock lose 75% of its value after presenting early data from VIP236, its potential first-in-class small-molecule-drug conjugate cancer therapy. That investor reaction was fueled

The second quarter of 2023 was a good news bad news situation for venture capital investment in biopharmaceutical companies, according to the latest Venture Monitor report from Pitchbook and the Natio

Biopharmaceutical companies raised $19.5bn in venture capital through the third quarter of 2020 and now Pitchbook and the National Venture Capital Association (NVCA) have revealed that the industry br

In two initiatives intended to increase the transparency of its coronavirus activities, the European Medicines Agency has published the clinical data that was used to support the EU marketing authoriz